Clinical Trial

Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 14, 2025 (before its estimated February 6, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, randomized, double-blind, multiple dose levels, parallal group, placebo-controlled study, to evaluate the safety, PK profiles and preliminary efficacy of TTYP01 tablets in adolescents and children with ASD.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-01-02; most recent amendment 2025-05-12.
Status change: Not Yet Recruiting → Recruiting 2025-01-07
Trial Details
NCT Number NCT06757504
Lead Sponsor Shanghai Auzone Biological Technology Co., Ltd.
Conditions Autism Spectrum Disorder (ASD)
Enrollment 150 participants
Start Date 2025-01-13
Primary Completion 2026-02-06 (estimated)
Study Completion 2026-05-08 (estimated)
Updated on ClinicalTrials.gov 2025-05-14